|
Tissue Engineering
A New Strategy Toward Improving Immunoprotection in Cell Therapy for Diabetes Mellitus: Long-Functioning PEGylated Islets In Vivo
To cite this article:
Dong Yun Lee, Sang Jin Park, Jong Hee Nam, Youngro Byun.
Tissue Engineering.
March 2006,
12(3): 615-623.
doi:10.1089/ten.2006.12.615.
Dong Yun Lee, Ph.D.College of Pharmacy, Seoul National University, Seoul, South Korea. Sang Jin Park, M.S.Center for Cell and Macromolecular Therapy, Department of Materials Science and Engineering, Gwangju Institute of Science and Technology, Gwangju, South Korea. Jong Hee Nam, M.D.Department of Pathology, School of Medicine, Chonnam National University, Gwangju, South Korea. Youngro Byun, Ph.D.College of Pharmacy, Seoul National University, Seoul, South Korea. Surface modification of islets using poly(ethylene glycol) (PEG) has been studied toward preventing immune responses of host for successful islet transplantation. In this study, we assessed the functionality of PEGylated islets and immune responses of host, as well as the synergistic effects of using PEGylation simultaneously with cyclosporine A (CsA) to prevent immune reactions. The average period of time for which PEGylated islets functioned normally following islets transplantation was 14 days, whereas it was only 5 days for unmodified islets. Host's immune cells did not eliminate the PEGylated islets but were observed to gather around the islets. On the other hand, unmodified islets were completely eliminated. When a low dose of CsA (3 mg/kg/day) was intravenously administered at the same time, the PEGylated islets showed stable activity and survived for 100 days before, that is, the PEGylated islets secreted insulin and were preserved from the immune cells. However, unmodified islets survived for 14 days on the average, even when CsA was administered. Consequently, it can be suggested that the PEGylation of islet surfaces can be an effective approach toward reducing the immunogenecity of islets, thus improving the functionality and survival time of transplanted islets, especially when CsA was simultaneously administered.  This paper was cited by:Human β-cell Precursors Mature Into Functional Insulin-producing Cells in an Immunoisolation Device: Implications for Diabetes Cell Therapies Seung-Hee Lee, Ergeng Hao, Alexei Y. Savinov, Ifat Geron, Alex Y. Strongin, Pamela Itkin-Ansari Transplantation. May 2009, Vol. 87, No. 7: 983-991 CrossRef Highly Poly(Ethylene) Glycolylated Islets Improve Long-Term Islet Allograft Survival without Immunosuppressive Medication Dong Yun Lee, Sang Jin Park, Seulki Lee, Jong Hee Nam, Youngro Byun Tissue Engineering. Aug 2007, Vol. 13, No. 8: 2133-2141 Abstract | Full Text PDF | Reprints & PermissionsIslet Encapsulation: Strategies to Enhance Islet Cell Functions Jonathan Beck, Ryan Angus, Ben Madsen, David Britt, Brent Vernon, Kytai T. Nguyen Tissue Engineering. Mar 2007, Vol. 13, No. 3: 589-599 Abstract | Full Text PDF | Reprints & PermissionsIslet Encapsulation: Strategies to Enhance Islet Cell Functions Jonathan Beck, Ryan Angus, Ben Madsen, David Britt, Brent Vernon, Kytai T. Nguyen Tissue Engineering. Feb 2007, Vol. 0, No. 0: 070104045812001 CrossRef Minimization of Immunosuppressive Therapy After Islet Transplantation: Combined Action of Heme Oxygenase-1 and PEGylation to Islet D. Y. Lee, S. Lee, J. H. Nam, Y. Byun American Journal of Transplantation. Sep 2006, Vol. 6, No. 8: 1820-1828 CrossRef
|
|